(3–11 mm). The outcomes of WEB treatment, coiling, and SAC were assessed in terms of morbidity, angiographic outcomes, retreatment rates, procedural and rehabilitation costs, and rupture rates. Incremental cost-effectiveness ratios (ICERs) were calculated for cost per quality-adjusted life year (QALY) and cost per year of neurological morbidity avoided. Uncertainty was explored using deterministic and probabilistic sensitivity analyses. Most of the data used were from prospective multicentre trials and meta-analyses of non-randomised trials.

**Results** In the base case, lifetime QALYs were 13.24 for WEB, 12.92 for SAC, and 12.68 for coiling. Lifetime costs were €20,440 for WEB, €23,167 for SAC, and €8,200 for coiling. Compared to coiling, WEB had an ICER of 21,826 €/QALY, while SAC was dominated by WEB. Probabilistic sensitivity analysis indicated WEB as the preferred treatment at a willingness-to-pay threshold of ≥30,000€/QALY. Deterministic sampling highlighted the discount rate, material costs and retreatment rates as having the greatest impact on ICERs.

**Conclusion** WEB treatment showed comparable or superior cost-effectiveness to SAC for wide-necked unruptured aneurysms, while coiling was the least expensive option but often inappropriate for wide-necked aneurysms.

**Disclosure of Interest** CK serves as consultant for Acandis GmbH (Pforzheim, Germany). CK and TL serve as proctors for MicroVention Inc./Sequent Medical (Aliso Viejo, CA, USA). David Zopfs is on the speaker’s bureau of Philips (Amsterdam, the Netherlands) and lecturer for Amboss GmbH (Cologne, Germany).

**P089/268** **SAFETY AND EFFICACY OF THE FOURTH-GENERATION ACANDIS ACCLINO FLEX PLUS STENT IN MANAGING COMPLEX INTRACRANIAL ANEURYSMS**

Lukas Goertz*, David Zopfs, Michael Schönfeld, Marc Schlamann, Christoph Kabbasch. University Hospital Cologne, Cologne, Germany

10.1136/jnis-2023-ESMINT.122

**Introduction** The Acandis Acclino Flex Plus (AFP) is a flexible, fourth-generation microstent designed to treat a wide range of aneurysms. It can be delivered through 0.017" microcatheters with stent diameters up to 5.5 mm.

**Aim of Study** To present our single-center experience with the AFP in the treatment of complex aneurysms.

**Methods** The AFP was used in 28 patients with 28 aneurysms. A retrospective analysis was performed to evaluate aneurysm characteristics, technical success, complications, clinical outcomes and angiographic results.

**Results** The cohort included 8 untreated unruptured aneurysms, 9 recurrent unruptured aneurysms and 12 ruptured aneurysms (diameters: 3–23 mm). The most common location was the anterior communicating artery (52%). Successful stenting was achieved in 28 cases (97%), with an average of 1.3 stents per aneurysm. The overall procedural complication rate was 17%, including two major clinical events (6.8%, an ischaemic stroke and an aneurysm perforation) and one minor clinical event (3.4%, a seizure). Follow-up angiographic results for 23 aneurysms at an average of 6 months post-procedure showed complete occlusion in 74%, neck remnants in 13% and aneurysm remnants in 13%. Three patients required retreatment.

**Conclusion** The AFP stent demonstrated feasibility and favourable safety and efficacy in the treatment of complex aneurysms. These results support its clinical use and highlight the need for further studies to evaluate its performance in different aneurysm subsets and to determine its specific role in the endovascular treatment of aneurysms.

**Disclosure of Interest** CK serves as consultants for Acandis GmbH (Pforzheim, Germany) and proctor for MicroVention Inc./Sequent Medical (Aliso Viejo, CA, USA). David Zopfs is on the speaker’s bureau of Philips (Amsterdam, the Netherlands) and lecturer for Amboss GmbH (Cologne, Germany). The other authors declare that they have no competing interests.

**P090/269** **COMPARATIVE ANALYSIS BETWEEN A SECOND-GENERATION (ACANDIS ACCLINO) AND A FIRST-GENERATION (ENTERPRISE) STENT SYSTEM**

1 Lukas Goertz*, 1 David Zopfs, 2 Michael Schönfeld, 2 Bend Turuski, 1 Marc Schlamann, 3 Christoph Kabbasch. 1University Hospital Cologne, Cologne, Germany; 2University Hospital Düsseldorf, Düsseldorf, Germany

10.1136/jnis-2023-ESMINT.123

**Introduction** Early evidence suggests the safety of second- and third-generation intracranial stents in the treatment of intracranial aneurysms.

**Aim of Study** This two-centre trial aims to directly compare the low-profile Acclino stent (Acandis) – a second-generation stent – with the first-generation Enterprise stent (Johnson & Johnson/Cerenovus).

**Methods** Patients who received Enterprise or Acclino stents for unruptured aneurysms were followed for 8 years. Complications, clinical and angiographic outcomes were compared with the primary outcomes of ischaemic stroke incidence and mid-term occlusion rate. Propensity score adjustment adjusted for group differences.

**Results** Both Enterprise and Acclino stents were used in the same number of cases (48 each). The analysis showed a higher incidence of thromboembolic complications in the Enterprise group (20.8% vs. 4.2%, HR: 6.6, 95%CI: 2.2–20.0, p=0.01, adjusted p<0.01) and a higher rate of major ischaemic stroke (6.3% vs. 0.%, HR: 21.95%CI: 1.8–24.2, p=0.08, adjusted p<0.01). However, there were no significant differences in mid-term or long-term angiographic outcomes, with procedural success rates of 83.3% and 75.0% for Enterprise and 89.2% and 75.9% for Acclino (both p>0.05). Retreatment rates were 10.4% in the Enterprise group and 4.2% in the Acclino group (p=0.42, adjusted p=0.10).

**Conclusion** Advanced stents offer reduced thromboembolic risk and comparable aneurysm occlusion to first-generation stents due to their flexible design and surface modification. These results support the clinical use of advanced stent systems, but further comparative studies are needed to conclusively evaluate the efficacy of stent-assisted coiling with the Acclino stent and other systems.

**Disclosure of Interest** CK serves as consultants for Acandis GmbH (Pforzheim, Germany) and proctor for MicroVention Inc./Sequent Medical (Aliso Viejo, CA, USA). David Zopfs is on the speaker’s bureau of Philips (Amsterdam, the Netherlands) and lecturer for Amboss GmbH (Cologne, Germany). The other authors declare that they have no competing interests.